U.S.-based Viatris has begun patient enrollment in Japan for a drug candidate to treat acute myocardial infarction. In its FY2025 results, revenue declined and operating profit was negative.
In the final installment of this series covering earnings at European and U.S. pharmaceutical companies, U.S.-based Viatris reports that it has also begun patient enrollment in Japan for a drug candidate to treat acute myocardial infarction. Japan is being added to the countries participating in the framework for the international trial.
The drug is selatogrel (ACT-246475), and plans have been indicated for Japan to participate in the Phase 3 clinical trial. The article treats the start of patient enrollment in Japan as a fact and reports on the expansion of the clinical trial.
In its overview of FY2025 results, Viatris reported a decline in revenue, while operating profit turned negative. It also emphasizes that net income was negative for the second consecutive period.
This article is part of a series for paid subscribers and is presented alongside other topics, including the world's top 10 pharmaceutical products by sales.